02 October 2015
The clinical data presented show the corneal inlay significantly improved near and intermediate uncorrected visual acuities across a 2.0 D range of preoperative refractive range (-0.5 D to +1.50 D) and age-related reading ADD powers between +1.50 D to +2.50 D. Near task performance was also significantly improved in good and dim light compared to preoperative levels. In the treated eye, the mean postoperative visual acuities were: 20/25 (near), 20/25 (intermediate), and 20/32 (distance). The clinical outcomes are explained by the center-near power profile of the cornea induced by the shape-changing inlay providing zones within the pupil for good near, intermediate, and distance image quality. And this thesis is confirmed by optical ray-trace predictions of visual acuity over this preoperative refractive range at distance, intermediate and near.
01 October 2015
Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today that results from a clinical trial of acebilustat in CF patients will be presented at the 29th North American Cystic Fibrosis Conference (NACFC) in Phoenix Oct 8-10, 2015.
28 September 2015
ReVision Optics, Inc. (RVO®), a leader in implantable presbyopia-correcting corneal inlay technology, announces the submission to the U.S. Food and Drug Administration (FDA) of the fourth and final module of the company’s Premarket Approval (PMA) application for the Raindrop® Near Vision Inlay. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or even eliminating the need for reading glasses. The fourth module includes clinical data from more than 300 subjects who have been followed for at least 24 months post-procedure.
Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
24 September 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the retina and choroid, today announced the enrollment of the 50th patient using Clearside’s proprietary ophthalmic drug administration platform for delivering drugs to the suprachoroidal space (SCS).
Atlas Genetics Ltd: Grant of Key US Patent
14 September 2015
Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid 'test and treat' molecular diagnostics company, today announces the granting of a key patent in its intellectual property portfolio.
Briggs Morrison, CEO, Syndax Pharmaceuticals To Open ACRES Inaugural SYNERGY Event
11 September 2015
Dr. Briggs Morrison, one of the world’s leading figures in drug development and immediate past Chairman of the Board of TransCelerate, an industry organization charged with improving the clinical trials process, will deliver the opening keynote address launching the Alliance for Clinical Research Excellence and Safety (ACRES) inaugural SYNERGY event to be held in Boston, October 1-2, 2015.
09 September 2015
Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA). The objective of the meeting was to obtain FDA feedback on the nonclinical and clinical programs to support registration of ganaxolone for the adjunctive treatment of focal onset seizures in adults.
Epic Sciences to Present at World CDx Boston 2015
02 September 2015
Epic Sciences, Inc. ("Epic Sciences"), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.
Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals As SVP And Chief Development Officer
01 September 2015
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today the hiring of industry veteran Michael Meyers, M.D., Ph.D. to the position of Senior Vice President and Chief Development Officer. Dr. Meyers, who will report to Briggs Morrison, M.D., Chief Executive Officer of Syndax, will become a member of the senior management team, and be responsible for all aspects of clinical development of entinostat, Syndax's oral, small molecule that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing anti-tumor immune responses.
27 August 2015
Cyber threats are one of the most significant risks businesses and individuals face today, says EPIC Insurance Brokers and Consultants. High profile breaches in the past few years have highlighted the substantial impact and significant costs associated with these attacks. And the breaches we hear about are just the tip of the iceberg, since information about an attack may not be revealed to the public if no personal data is stolen.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024